Ibáñez-Mejía SM, Juárez-Durán ER, Cortés LPN, Arenas R

Language: Spanish
References: 27
Page: 259-263
PDF size: 200.97 Kb.

ABSTRACT

Recently, diabetes has been a global health problem. According to the International Diabetes Federation, globally, 537 million adults between the ages of 20 and 79 are living with diabetes (one in ten), this number is expected to rise to 643 million by 2030 and 783 million by 2045. In Central and South America, it is mentioned that one in 11 adults (32 million) lives with diabetes, however, one in three patients living with diabetes are not diagnosed. It has been estimated that more than 30% of patient’s presented skin manifestations at the beginning of the disease and, up to 100% during its course. In our study, skin infections, mainly mycosis were one of the most common skin manifestations of diabetes.

REFERENCES

1. Fuentes A y Mondragón M, La importancia de la piel en la diabetesmellitus, Medicina e Investigación 2015; 3:61-73.

2. Behm B, Schreml S, Landthaler M y Babilas P, Skin signs in diabetesmellitus, jeadv 2012; 26:1203-11.

3. Murphy B, Han G y Cohen S, Dermatologic manifestations ofdiabetes mellitus: a review, Endocrinol Metab Clin N Am 2013; 42:869-98.

4. Senet P, Manifestaciones mucocutáneas de la diabetes, emcDermatología 2019; 53:1-8.

5. De Macedo G, Nunes S y Barreto T, Skin disorders in diabetesmellitus: an epidemiology and physiopathology review, DiabetolMetab Syndr 2016; 8:63.

6. Sakai S, Kikuchi K, Satoh J, Tagami H e Inoue S, Functionalproperties of the stratum corneum in patients with diabetesmellitus: similarities to senile xerosis, Br J Dermatol 2005;153:319-23.

7. Bustan R, Wasim D, Yderstræde K y Bygum A, Specific skinsigns as a cutaneous marker of diabetes mellitus and the prediabeticstate: a systematic review, Dan Med J 2017; 64:A5316.

8. Aoki M y Murase T, Obesity-associated insulin resistance adverselyaffects skin function, plos One 2019; 14:e0223528.

9. Blakytny R y Jude E, Altered molecular mechanisms of diabeticfoot ulcers, Int J Low Extrem Wounds 2009; 2:95-104.

10. Berbudi A, Rahmadika N, Tjahjadi A y Ruslami R, Type 2 diabetesand its impact on the immune system, Curr Diabetes Rev 2020;16(5):442-9.

11. Martínez N, Ketheesan N, Martens G, West K, Lien E y KornfeldH, Defects in early cell recruitment contribute to the increasedsusceptibility to respiratory Klebsiella pneumoniae infection indiabetic mice, Microbes Infect 2016; 18(10):649-55.

12. Gupta AK, Versteeg SG y Shear NH, Onychomycosis in the 21st Century:an update on diagnosis, epidemiology, and treatment, J CutanMed Surg 2017; 21(6):525-39. doi: 10.1177/1203475417716362.

13. Cohen E, La glicosilación no enzimática: una vía común en la diabetesy el envejecimiento, Med Cutan Iber Lat Am 2011; 39:243-6.

14. Goyal A, Raina S, Kaushal S, Mahajan V y Sharma NL, Pattern ofcutaneous manifestations in diabetes mellitus, Indian J Dermatol2010; 55:39-41.

15. Kataria U, Chhillar D, Kumar H y Chhikara P, Cutaneous manifestationsof diabetes mellitus in controlled and uncontrolled state,iaim 2015; 2:90-3.

16. Gupta S y Parminder M, Pattern of dermatological diseases inpatients of diabetes mellitus, jpad 2016; 26:214-8.

17. Crizón D y Morales C, Manifestaciones dermatológicas de ladiabetes: clasificación y diagnóstico, Iatreia 2020; 33:239-50.

18. Gupta A y Humke S, The prevalence and management of onychomycosisin diabetic patients, Eur J Dermatol 2000; 10:379-84.

19. Bouza E, Muñoz P y Guinea J, Mucormycosis: an emerging disease?,Clin Microbiol Infect 2006; 12:7-23.

20. Garg D, Muthu V, Sehgal I, Ramachandran R, Kaur H, Bhalla Aet al., Coronavirus disease (covid-19) associated mucormycosis(cam): case report and systematic review of literature, Mycopathologia2021; 186(2):289-98.

21. Gangneux J, Bougnoux M, Dannaoui E, Cornet M y Zahar J, Invasivefungal diseases during covid-19: We should be prepared,J Mycol Med 2020; 30(2):100971.

22. Mehta S y Pandey A, Rhino-orbital mucormycosis associatedwith covid-19, Cureus 2020; 12:e10726.

23. Sarkar S, Gokhale T, Choudhury S y Deb A, covid-19 and orbitalmucormycosis, Indian J Ophthalmol 2021; 69(4):1002-4.

24. Cornely O, Izquierdo A, Arenz D, Chen S, Dannaoui E, HochheggerB et al., Global guideline for the diagnosis and managementof mucormycosis: an initiative of the European Confederationof Medical Mycology in cooperation with the Mycoses StudyGroup Education and Research Consortium, Lancet Infect Dis2019; 19(12):e405-21.

25. Arenas, R, Dermatología. Atlas, diagnóstico y tratamiento, 7ªed., México, McGraw Hill, 2019.

26. DiPiro JT, Pharmacotherapy: a pathophysiologic approach, 11ªed., Nueva York, McGraw Hill, 2020.

27. Rodríguez, Vademécum académico de medicamentos, 6ª ed.,México, McGraw Hill, 2013.